Anti-CD20-mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32229095.
- Also identified by DOI 10.1016/j.kint.2019.12.025.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
B-cell depletion with anti-CD20 monoclonal antibodies is widely used for the treatment of autoimmune diseases. This review will discuss mechanisms contributing to success or failure of B-cell depletion therapy in antibody-mediated autoimmune diseases. It will also explain how key information about disease pathogeny can be provided by the different outcomes observed after B-cell depletion therapy. These findings provide the basis for future innovative therapeutic strategies aiming at an optimized B cell and/or plasma cell depletion to increase long-term disease remission.
Medical subject headings
- Autoimmune Diseases
- Lupus Erythematosus, Systemic